Raghav Sundar

National Cancer Institute

Singapore

Research Interests

Explore related searches

Professors in Cancer Biology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Melissa Fullwood

Nanyang Technological University (NTU)

SINGAPORE

View details

Jiaqi Li

Stanford University

UNITED STATES

View details

Milad Razavi Mohseni

Johns Hopkins University

UNITED STATES

View details

Wim Ceelen

Ghent University Hospital

BELGIUM

View details

Atsushi Okabe

Chiba University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Raghav Sundar

Research Interests

Explore related searches

Contact this professor

Articles (21)

Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination

Evolution of claudin18.2 therapies in gastroesophageal cancers

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

Reply

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal Metastasis

Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases

Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases

Consensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer

Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials

Immune checkpoint inhibitor combinations—current and emerging strategies

Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities

First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis

Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies

Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”

Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis

Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer

Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies

Resistance to systemic immune checkpoint inhibition in the peritoneal niche

Collaborators (5)

Melissa Fullwood

Jiaqi Li

Milad Razavi Mohseni

Wim Ceelen

Atsushi Okabe

Make your next move.